Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction DOI Creative Commons

Nicia I. Profili,

Roberto Castelli, Roberto Manetti

и другие.

Biomedicines, Год журнала: 2025, Номер 13(3), С. 720 - 720

Опубликована: Март 15, 2025

Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a specific class of drugs originally developed for treating type 2 diabetes mellitus. Subsequently, studies demonstrated that their action was not limited to glycemic control but could also have positive effects on other outcomes, particularly at the cardiovascular level. Indeed, due diuretic effect, SGLT2i improve clinical chronic heart failure and reduce risk rehospitalization. In addition, reported protective effect major events mortality. More recently, it has been suggested prescription after an acute myocardial infarction may possible inflammation, arrhythmias, ventricular remodeling. Here, we reviewed focused in patients treated with percutaneous coronary intervention.

Язык: Английский

Perivascular adipose tissue: a central player in the triad of diabetes, obesity, and cardiovascular health DOI Creative Commons
Marcelo Queiroz, Cristina M. Sena

Cardiovascular Diabetology, Год журнала: 2024, Номер 23(1)

Опубликована: Дек. 28, 2024

Perivascular adipose tissue (PVAT) is a dynamic that affects vascular function and cardiovascular health. The connection between PVAT, the immune system, obesity, disease complex plays pivotal role in pathogenesis of diseases such as atherosclerosis, hypertension, inflammation. In cardiometabolic diseases, PVAT becomes significant source proflammatory adipokines, leading to increased infiltration cells, proinflammatory promoting smooth muscle cell proliferation migrationpromoting migration. This exacerbates dysfunction by impairing endothelial activation. Dysregulated also contributes hemodynamic alterations hypertension through enhanced sympathetic nervous system activity impaired vasodilatory capacity PVAT-derived factors. Therapeutic interventions targeting key components this interaction, modulating inflammation, restoring adipokine balance, attenuating activation, hold promise for mitigating obesity-related complications. Lifestyle interventions, pharmacological agents inflammatory pathways, surgical approaches aimed at reducing mass or improving are potential therapeutic avenues managing associated with obesity dysfunction.

Язык: Английский

Процитировано

3

Clinical predictive model of new-onset atrial fibrillation in patients with acute myocardial infarction after percutaneous coronary intervention DOI Creative Commons
Xiaodan Wu, Wei Zhao, Quanwei Wang

и другие.

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Янв. 2, 2025

New-onset atrial fibrillation (NOAF) is associated with increased morbidity and mortality. Despite identifying numerous factors contributing to NOAF, the underlying mechanisms remain uncertain. This study introduces triglyceride-glucose index (TyG index) as a predictive indicator establishes clinical model. We included 551 patients acute myocardial infarction (AMI) without history of (AF). These were divided into two groups based on occurrence postoperative NOAF during hospitalization: group (n = 94) sinus rhythm (SR) 457). utilized regression model analyze risk establish The performance, calibration, effectiveness evaluated using receiver operational characteristics (ROC), calibration curve, decision curve analysis, impact curve. 94 developed hospitalization. TyG was identified an independent predictor significantly higher in group. Left (LA) diameter, age, systemic inflammatory response (SIRI), creatinine also for NOAF. Combining these build prediction resulted area under (AUC) 0.780 (95% CI 0.358–0.888). ROC, demonstrated that performance new nomogram satisfactory. By incorporating model, after AMI hospitalization can be effectively predicted. Early detection improve prognosis patients.

Язык: Английский

Процитировано

0

The monocyte-to-HDL-cholesterol ratio predicts new-onset atrial fibrillation in patients with acute STEMI DOI
Veysel Ozan Tanık, Çağatay Tunca, Kamuran Kalkan

и другие.

Biomarkers in Medicine, Год журнала: 2025, Номер unknown, С. 1 - 8

Опубликована: Янв. 29, 2025

Newly diagnosed AF (NOAF) associated with acute STEMI holds significant relevance in clinical practice. This study seeks to assess the role of monocyte HDL-C ratio (MHR) predicting NOAF these patients. Between July 2017 and May 2018, 663 patients who underwent primary PCI for were retrospectively analyzed. was identified 34 (5.1%), this group compared those without AF. The experienced a longer hospitalization duration higher mortality rate (11.8 vs. 4.3%, p = 0.044) non-AF group. In multivariable analysis, increased MHR (OR: 1.413, 95% CI: 1.203-1.657, 0.005), advanced age, decreased LVEF, Killip class 2-4, diabetes mellitus, hypertension, left atrial enlargement emerged as independent predictors development STEMI. ROC curve analysis revealed that values exceeding 26.54 strongly predict NOAF, achieving sensitivity specificity above 70% (AUC: 0.768, 95%CI: 0.734-0.801, < 0.001). present robust indicator can be easily assessed Incorporating alongside established traditional risk factors may enhance identification at

Язык: Английский

Процитировано

0

Euglycemic Diabetic Ketoacidosis in a Patient Treated With Empagliflozin After Acute Myocardial Infraction DOI

George Tournas,

Argyro Papadopoulou,

Polyxeni Manifava

и другие.

American Journal of Therapeutics, Год журнала: 2025, Номер unknown

Опубликована: Фев. 28, 2025

Tournas, George; Papadopoulou, Argyro MSc; Manifava, Polyxeni; Tselegkidi, Maria Eirini; Dimoula, Anna; Nastatos, Panagiotis MD; Tsagalou, Eleftheria; Briasoulis, Alexandros; Stamatelopoulos, Kimon PhD Author Information

Язык: Английский

Процитировано

0

Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction DOI Creative Commons

Nicia I. Profili,

Roberto Castelli, Roberto Manetti

и другие.

Biomedicines, Год журнала: 2025, Номер 13(3), С. 720 - 720

Опубликована: Март 15, 2025

Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a specific class of drugs originally developed for treating type 2 diabetes mellitus. Subsequently, studies demonstrated that their action was not limited to glycemic control but could also have positive effects on other outcomes, particularly at the cardiovascular level. Indeed, due diuretic effect, SGLT2i improve clinical chronic heart failure and reduce risk rehospitalization. In addition, reported protective effect major events mortality. More recently, it has been suggested prescription after an acute myocardial infarction may possible inflammation, arrhythmias, ventricular remodeling. Here, we reviewed focused in patients treated with percutaneous coronary intervention.

Язык: Английский

Процитировано

0